drugset

drugset / Trial / NCT00494585

CEP-701 for PH-negative Myelofibrosis

NCT00494585 ↗

Phase 2 Completed 27 enrolled M.D. Anderson Cancer Center Cephalon · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find out if CEP-701 can help control myelofibrosis (MF). The safety of CEP-701 will also be studied.

Timeline

Start: 2007-06
Primary completion: 2010-05
Completion: 2010-05

Publications

Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11;115(6):1131-6. doi: 10.1182/blood-2009-10-246363. Epub 2009 Dec 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	lestaurtinib	Small molecule	80 mg	Oral

Indications